US Supreme Court IEEPA Ruling Reshapes Banking Landscape as Tariff Rates Shift Overnight

WASHINGTON, February 22, 2026 - The U.S. Supreme Courts landmark 6-3 decision on February 20, 2026, declaring that the International Emergency Economic Powers Act (IEEPA) does not authorize tariff imposition has sent shockwaves through the banking and trade finance sectors.

The Courts decision centered on a constitutional question of considerable importance: whether the IEEPA, enacted during the Cold War era, extends to trade tariff implementation. The majority opinion concluded that the statutes language and legislative history do not support such a broad interpretation.

The immediate market impact was swift and dramatic. Tariff rates dropped from 12.7 percent to 8.3 percent within hours. However, the administration invoked Section 232 of the Trade Expansion Act of 1962, pushing rates to 10.7 percent.

This decision represents a constitutional boundary-setting moment that will affect trade policy for years to come, explained Professor Jonathan Hartley, Chair of International Trade Law at Georgetown University Law Center.

The pharmaceutical sector faces potential elevation to 200 percent tariffs under Section 232 national security rationale, with profound implications for drug pricing and the global pharmaceutical supply chain.

Cross-border transaction flows are already being reassessed. Banking compliance departments are reviewing whether tariff changes create obligations to modify client reporting or risk assessments.

The Federal Reserve and the OCC have issued guidance reminding banks that tariff policy changes may require adjustments to credit risk assessments. The 10.7 percent tariff rate appears to be a temporary equilibrium rather than a final outcome.